Transition Therapeutics Inc. (TTHI) announced the results of a 5-week proof of concept clinical study of TT-401 Tuesday morning, in type 2 diabetic and obese non-diabetic subjects. TT-401 demonstrated significant improvements in glycemic control and reductions in body weight.
Transition Therapeutics gapped up Tuesday and has since risen sharply on strong volume. The stock is now up 1.30 at $3.55 and has surged to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.